|
Renal fibrosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
MicroRNA21 promotes interstitial fibrosis via targeting DDAH1: a potential role in renal fibrosis.
|
26455824 |
2016 |
|
Renal fibrosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Innovation and Conclusion: Our results provide the first direct evidence that the DDAH1 has a marked effect on kidney fibrosis and oxidative stress induced by aging or diabetes.
|
28594240 |
2017 |
|
Hyperhomocysteinemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that suppression of DDAH2 expression is a culprit for homocysteine-induced impairments of DDAH/ADMA/NOS/NO pathway in endothelial cells, and therapeutic manipulation of DDAH2 expression may be a promising strategy for preventing endothelial dysfunction and cardiovascular diseases associated with hyperhomocysteinemia.
|
23171931 |
2012 |
|
Hyperhomocysteinemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of DDAH1 protects from hyperhomocysteinemia-induced alterations in cerebral arteriolar structure and vascular muscle function.
|
20019334 |
2010 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
This study represents the first evidence for therapeutic inhibition of DDAH1 by small molecules in breast cancer.
|
30611984 |
2019 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Here, we identified over-expression of DDAH1 in aggressive MDA-MB-231, MDA-MB-453 and BT549 breast cancer cell lines when compared to normal mammary epithelial cells.
|
29070803 |
2017 |
|
Coronary Artery Disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
DDAH1 rs997251 TC + CC genotypes were associated with 2.3-fold higher risk of CAD than TT genotype (p = 0.0063).
|
30284143 |
2018 |
|
Coronary Artery Disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
A novel loss-of-function DDAH1 promoter polymorphism is associated with increased susceptibility to thrombosis stroke and coronary heart disease.
|
20167924 |
2010 |
|
Alzheimer's Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our findings suggest that strategies to increase DDAH1 activity in neuronal cells may be a novel approach to attenuating AD development.
|
25499850 |
2015 |
|
Amyloidosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
However, overexpression of dimethylarginine dimethylaminohydrolase 1 (DDAH1) to promote ADMA degradation significantly attenuated oxidative stress and Aβ secretion in APPsw cells.
|
25499850 |
2015 |
|
Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In human subjects (n = 89) the FoxO1/DDAH1/ADMA pathway marks unstable atherosclerosis.
|
26226438 |
2015 |
|
Rheumatoid Arthritis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The results of our study give no evidence to suggest that increased ADMA levels in RA relate to DDAH genetic polymorphisms.
|
25194333 |
2014 |
|
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In human subjects (n = 89) the FoxO1/DDAH1/ADMA pathway marks unstable atherosclerosis.
|
26226438 |
2015 |
|
Bronchopulmonary Dysplasia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The rs480414 SNP in DDAH1 may be protective against the development of PH in patients with BPD.
|
26663142 |
2016 |
|
Carotid Artery Thrombosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
DDAH1 Tg mice also were protected from hypertrophy of cerebral arterioles (P<0.05) but not from accelerated carotid artery thrombosis induced by the HM/LF diet.
|
20019334 |
2010 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We found limited evidence that genetic polymorphisms in DDAH genes influence serum ADMA levels in individuals with T1DM.
|
22521321 |
2012 |
|
Fatty Liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, we used Ddah1<sup>-/-</sup> mice to investigate the effects of the ADMA/DDAH1 pathway on high-fat diet (HFD)-induced hepatic steatosis.
|
27565538 |
2017 |
|
Heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we examine mechanisms of abnormal NO production in heart failure, with particular focus on the role of ADMA and DDAH1.
|
26923818 |
2016 |
|
Malignant neoplasm of stomach
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we found that downregulation of DDAH1 was frequently detected in GC tissues and strongly correlated with more aggressive phenotypes and poor prognosis.
|
28580735 |
2017 |
|
Pulmonary Fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, DDAH1 knockout significantly aggravated monocrotaline-induced lung and RV oxidative stress, lung vascular remodeling and fibrosis, pulmonary hypertension and RV hypertrophy in rats.
|
31402164 |
2019 |
|
Septicemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Inhibition of Dimethylarginine Dimethylaminohydrolase 1 Improves the Outcome of Sepsis in Pregnant Mice.
|
31821207 |
2019 |
|
Left Ventricular Hypertrophy
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In contrast, cDDAH1 KO mice exposed to TAC showed no increase in LV DDAH1 expression, slightly increased LV tissue ADMA levels, no increase in plasma ADMA, but significantly exacerbated LV hypertrophy, fibrosis, nitrotyrosine production, and LV dysfunction.
|
28819685 |
2017 |
|
Myocardial Ischemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Asymmetric dimethylarginine had and OR of 1.08 per SD (95% CI 0.99-1.19) for IHD based on 4 SNPs from DDAH1.
|
27914500 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overall, our data revealed that long non-coding RNA H19 confers resistance to gefitinib via miR-148b/dimethylarginine dimethylaminohydrolase-1 axis in lung adenocarcinoma, which offers a new insight into the epidermal growth factor receptor tyrosine kinase inhibitors therapy resistance.
|
31503013 |
2020 |
|
Acute myocardial infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
Herein, we used an inducible cardiac-specific DDAH1 knockdown mouse (cardiac DDAH1<sup>-/-</sup>) to investigate the role of cardiomyocyte DDAH1 in left-ventricular (LV) remodeling after acute myocardial infarction (AMI).
|
29892894 |
2018 |